Potassium citrate oral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of potassium citrate.
Cystitis - adjunctive therapy
For the symptomatic relief of dysuria associated with mild urinary tract infections, especially cystitis.
10ml (well diluted with water) three times a day.
One sachet three times a day for two days. All six sachets must be taken to complete course.
Children aged 6 to 18 years: 10ml (well diluted with water) three times a day.
Children aged 1 to 5 years: 5ml (well diluted with water) three times a day.
Children under 1 year: Contraindicated.
Children aged 6 to 18 years: One sachet three times a day for two days. All six sachets must be taken to complete course.
Children under 6 years: Contraindicated.
Children under 1 year
Hereditary fructose intolerance
Severe renal impairment
Precautions and Warnings
Glucose-galactose malabsorption syndrome
Mild renal impairment
Some formulations contain aspartame - caution in phenylketonuria
Not all available brands are licensed for all age groups
Some formulations contain sucrose
Advise patient to consult a doctor if symptoms persist despite treatment
Pregnancy and Lactation
Use potassium citrate with caution during pregnancy.
The manufacturer advises pregnant women should seek medical advice on the treatment of cystitis rather than self-treatment with potassium citrate. If drug treatment is needed in pregnancy, potassium citrate can be used if no safer alternative.
At the time of writing there is limited published information regarding the use of potassium citrate in pregnancy but it has been in use for many years without apparent ill consequence.
High potassium levels may occur in patients who have a condition predisposing them to high potassium levels. Monitor potassium levels as high potassium levels are detrimental to maternal and embryo-foetal cardiac function.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Potassium citrate is considered safe for use in breast feeding.
At the time of writing there is limited published information regarding the use of potassium citrate in breastfeeding.
Potassium is present in human breast milk and passes freely into and out of milk. In women with normal plasma potassium levels, no adverse effects are anticipated in the breast fed infant.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Advise patient potassium citrate mixture should be well diluted with water before taking.
Advise patient potassium citrate sachets should be dissolved in 200mls of cold water before taking.
Advise patient to consult a doctor if symptoms persist despite treatment.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: December 2018
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.
Summary of Product Characteristics: Potassium Citrate Mixture. Thornton and Ross. Revised July 2015.
Summary of Product Characteristics: Cystopurin. Bayer Plc. Revised August 2018.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 07 December 2018
Specialist Pharmacy Service (SPS)
Available at: https://www.sps.nhs.uk/
Potassium citrate Last revised: 17 April 2016
Last accessed: 06 December 2018
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.